Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Outcome of tailored antiplatelet therapy in carotid stenting: a retrospective comparative study

P. Vigláš, V. Smolka, J. Raupach, A. Hejčl, D. Černík, F. Cihlář

. 2024 ; 7 (1) : 73. [pub] 20241009

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002405

BACKGROUND: Carotid stenting requires dual antiplatelet therapy to effectively prevent thromboembolic complications. However, resistance to clopidogrel, a key component of this therapy, may lead to persistent risk of these complications. The aim of this study was to determine, if the implementation of routine platelet function testing and adjusting therapy was associated with lower incidence of thromboembolic complications and death. METHODS: All consecutive patients treated with carotid artery stenting in a single institution over 8 years were enlisted in a retrospective study. Platelet function testing was performed, and efficient antiplatelet therapy was set before the procedure. Incidence of procedure-related stroke or death within periprocedural period (0-30 days) was assessed. The results were evaluated in relation to the findings of six prominent randomized control trials. RESULTS: A total of 241 patients were treated for carotid stenosis, seven patients undergo CAS on both sides over time. There was 138 symptomatic (55,6%) and 110 asymptomatic stenoses (44,4%). Five thromboembolic complications (2,01%) occurred, four of them (1,61%) was procedure-related. Two patients died because of procedure-related stroke (0,82%). Incidence of procedure-related stroke or death was significant lower compared to the results of CREST study (2,01% vs. 4,81%, P = 0,0243) in the entire cohorts, and to the results of ICSS study in the symptomatic cohorts (2,86% vs. 7,37%, P = 0,0243), respectively. CONCLUSIONS: Tailored antiplatelet therapy in carotid stenting is safe and seems to be related with lower incidence of procedure-related death or stroke rate. Larger prospective studies to assess whether platelet function testing-guided antiplatelet therapy is superior to standard dual antiplatelet should be considered.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002405
003      
CZ-PrNML
005      
20250123101927.0
007      
ta
008      
250117s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s42155-024-00482-2 $2 doi
035    __
$a (PubMed)39379742
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vigláš, Pavol $u Deptartment of Radiology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic $u Deptartment of Radiology, Masaryk hospital - J.E. Purkinje University and KZ a .s., Ústí nad Labem, Czech Republic $1 https://orcid.org/0009000133800368
245    10
$a Outcome of tailored antiplatelet therapy in carotid stenting: a retrospective comparative study / $c P. Vigláš, V. Smolka, J. Raupach, A. Hejčl, D. Černík, F. Cihlář
520    9_
$a BACKGROUND: Carotid stenting requires dual antiplatelet therapy to effectively prevent thromboembolic complications. However, resistance to clopidogrel, a key component of this therapy, may lead to persistent risk of these complications. The aim of this study was to determine, if the implementation of routine platelet function testing and adjusting therapy was associated with lower incidence of thromboembolic complications and death. METHODS: All consecutive patients treated with carotid artery stenting in a single institution over 8 years were enlisted in a retrospective study. Platelet function testing was performed, and efficient antiplatelet therapy was set before the procedure. Incidence of procedure-related stroke or death within periprocedural period (0-30 days) was assessed. The results were evaluated in relation to the findings of six prominent randomized control trials. RESULTS: A total of 241 patients were treated for carotid stenosis, seven patients undergo CAS on both sides over time. There was 138 symptomatic (55,6%) and 110 asymptomatic stenoses (44,4%). Five thromboembolic complications (2,01%) occurred, four of them (1,61%) was procedure-related. Two patients died because of procedure-related stroke (0,82%). Incidence of procedure-related stroke or death was significant lower compared to the results of CREST study (2,01% vs. 4,81%, P = 0,0243) in the entire cohorts, and to the results of ICSS study in the symptomatic cohorts (2,86% vs. 7,37%, P = 0,0243), respectively. CONCLUSIONS: Tailored antiplatelet therapy in carotid stenting is safe and seems to be related with lower incidence of procedure-related death or stroke rate. Larger prospective studies to assess whether platelet function testing-guided antiplatelet therapy is superior to standard dual antiplatelet should be considered.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Smolka, Vojtěch $u Deptartment of Radiology, Masaryk hospital - J.E. Purkinje University and KZ a .s., Ústí nad Labem, Czech Republic
700    1_
$a Raupach, Jan $u Deptartment of Radiology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic. jan.raupach@fnhk.cz $u Department of Radiology, University Hospital Hradec Králové, Hradec Kralove, Czech Republic. jan.raupach@fnhk.cz
700    1_
$a Hejčl, Aleš $u Department of Neurosurgery Masaryk Hospital -J.E. Purkinje University and KZ a.s., Ústí nad Labem, Czech Republic
700    1_
$a Černík, David $u Deptartment of Neurology, Masaryk Hospital - Ústí nad Labem, Czech Republic
700    1_
$a Cihlář, Filip $u Deptartment of Radiology, Masaryk hospital - J.E. Purkinje University and KZ a .s., Ústí nad Labem, Czech Republic
773    0_
$w MED00203270 $t CVIR endovascular $x 2520-8934 $g Roč. 7, č. 1 (2024), s. 73
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39379742 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101921 $b ABA008
999    __
$a ok $b bmc $g 2254562 $s 1238408
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 7 $c 1 $d 73 $e 20241009 $i 2520-8934 $m CVIR endovascular $n CVIR Endovasc $x MED00203270
LZP    __
$a Pubmed-20250117

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace